BioCryst Pharmaceuticals, Inc.
BCRX
$6.82
$0.416.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 450.71M | 412.58M | 382.24M | 355.40M | 331.41M |
| Total Other Revenue | -- | 2.52M | 3.58M | 5.06M | 5.42M |
| Total Revenue | 450.71M | 412.58M | 382.24M | 355.40M | 331.41M |
| Cost of Revenue | 187.12M | 198.67M | 202.37M | 215.21M | 216.65M |
| Gross Profit | 263.59M | 213.91M | 179.86M | 140.18M | 114.76M |
| SG&A Expenses | 266.13M | 249.69M | 235.25M | 225.04M | 213.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 453.26M | 448.36M | 437.63M | 440.25M | 430.19M |
| Operating Income | -2.54M | -35.78M | -55.39M | -84.85M | -98.78M |
| Income Before Tax | -86.95M | -124.13M | -146.50M | -208.58M | -226.23M |
| Income Tax Expenses | 1.93M | -308.00K | -564.00K | 4.00K | 310.00K |
| Earnings from Continuing Operations | -88.88 | -123.82 | -145.93 | -208.59 | -226.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.88M | -123.82M | -145.93M | -208.59M | -226.54M |
| EBIT | -2.54M | -35.78M | -55.39M | -84.85M | -98.78M |
| EBITDA | 469.00K | -33.21M | -52.71M | -82.09M | -95.91M |
| EPS Basic | -0.43 | -0.61 | -0.73 | -1.07 | -1.18 |
| Normalized Basic EPS | -0.26 | -0.37 | -0.44 | -0.56 | -0.62 |
| EPS Diluted | -0.43 | -0.61 | -0.73 | -1.07 | -1.18 |
| Normalized Diluted EPS | -0.26 | -0.37 | -0.44 | -0.56 | -0.62 |
| Average Basic Shares Outstanding | 826.78M | 820.80M | 803.54M | 786.24M | 768.68M |
| Average Diluted Shares Outstanding | 826.78M | 820.80M | 803.54M | 786.24M | 768.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
